Back to marketplace
SIGACHILABORATORIESLIMITEDU· ISIN INE368H01018· Hyderabad, Telangana, India· Est. 1989 Verified
Sigachi Laboratories Limited Unlisted Shares logo

Sigachi Laboratories Limited Unlisted Shares

Pharmaceuticals
₹52+0.00%

vs. prev. close ₹52

52W High

₹52

52W Low

₹52

Market cap

₹35 Cr

IPO stage

No DRHP filed

CIN

L24230TG1994PLC018786

Price History

52W High

₹52

52W Low

₹52

About Sigachi Laboratories Limited Unlisted Shares

Sigachi Laboratories Limited, a Telangana-based bulk drug manufacturer currently earning most of its income from leasing out its two factories and a Rs 31.45 crore investment portfolio, posted FY26 profit of Rs 1.34 crore on revenue of Rs 3.26 crore (EPS Rs 1.98, ROE 3.28%), debt-free across both years shown.

The Short Version :

Sigachi Laboratories Limited, a Hyderabad/Telangana-based bulk drug and drug intermediates manufacturer whose shares are listed on the Metropolitan Stock Exchange of India Limited, currently earns most of its income from leasing out its two factories rather than active manufacturing, alongside a sizeable investment portfolio of Rs 31.45 crore in non-current investments. Revenue from operations rose to Rs 3.26 crore in FY26 from Rs 3.12 crore in FY25, and profit for the year rose to Rs 1.34 crore from Rs 1.19 crore, taking EPS to Rs 1.98 from Rs 1.76, book value per share to Rs 60.54 from Rs 58.24, and ROE to 3.28% from 3.03% on closing equity of Rs 40.88 crore.

Why It Trades Where It Does :

This is effectively an asset-holding and lease-income business rather than an operating pharmaceutical manufacturer at present: cost of materials consumed is nil, both factories are leased out, and the bulk of reported income comes from lease rentals, dividend income (Rs 0.55 crore), and interest income (Rs 0.88 crore) on a large investment book. Fair value movements on that investment portfolio swing the P&L meaningfully year to year (Rs 1.29 crore of fair value losses partly offset by Rs 0.98 crore of fair value gains in FY26 alone), so reported profit is sensitive to market movements in the underlying investments, not to manufacturing volumes. The company remains asset-heavy and debt-free, with essentially no borrowings on either side of the balance sheet.

Top Risks :

  • The company currently derives its income from leased-out factories and investment returns rather than active manufacturing, so an investor is effectively buying exposure to a real estate and investment holding structure carrying a pharma manufacturing license, not an operating drug business.

  • Reported profit is directly exposed to fair value swings on the investment portfolio, Rs 1.29 crore of fair value losses were booked in FY26 alone, a volatility source that has nothing to do with the underlying leased factories.

  • ROE remains thin at 3.28%, meaningfully below what an operating manufacturer with this asset base would typically be expected to generate, reflecting the current non-operating structure.

  • Trading on the Metropolitan Stock Exchange of India Limited carries materially lower liquidity than the main exchanges, a genuine structural constraint on exit even though the shares are technically listed.

Top Opportunities :

  • The company is debt-free with zero borrowings on the balance sheet across both years, giving it full flexibility to redeploy the Rs 31.45 crore investment book or restart manufacturing operations without any leverage overhang.

  • Both factories remain intact and leased rather than sold, preserving the option to resume active bulk drug manufacturing if market conditions or company strategy change.

  • Profit and EPS both grew year-on-year even with fair value volatility working against the P&L, indicating the underlying lease and treasury income base is stable and growing.

  • The Rs 31.45 crore non-current investment portfolio, against a market cap that reflects a thinly-traded small-cap listing, means the asset backing per share is a significant portion of the current book value.


Disclaimer :

Priveq.in is an informational platform for unlisted and pre-IPO shares, operated by Priveq Investech Private Limited (the named counterparty on transactions). Unlisted shares carry risks including illiquidity, valuation uncertainty, and limited regulatory disclosure. This page is informational only and does not constitute investment advice.

Company Details

Industry

Pharmaceuticals

Founded

1989

Headquarters

Hyderabad, Telangana, India

Min Lot Size

1500

Face Value

₹10.00

Shares Outstanding

67,53,100

Regulatory Information

Corporate Identity Number (CIN)

L24230TG1994PLC018786

PAN Number

AACCS8220M

ISIN

INE368H01018

Key Valuation Ratios

As of FY2026 Annual · updated 20 Sept 2026Derived

Valuation

Market Cap

₹35.12 Cr

P/E Ratio

26.21×

P/S Ratio

10.78×

P/B Ratio

0.86×

EV / EBITDA

16.79×

Returns & Per Share

ROE

3.28%

EPS

₹1.98

Book Value / Share

₹60.54

Solvency

Debt / Equity

0.00×

Interest Coverage

624.79×

Company Fundamentals

As of FY2026 Annual · updated 20 Sept 2026

Gross Profit

₹3.26 Cr

EBITDA

₹2.07 Cr

Revenue Growth

4.33%

Profit Margin

41.13%

Performance Trends

5 annual periods · derived from filed statements

As of FY2026 Annual · updated 20 Sept 2026

Revenue

₹ Cr

Net Profit

₹ Cr · losses in red

Earnings Per Share

₹ per share

Return on Equity

ROE %

Return on Capital Employed

ROCE %

Debt-to-Equity

0.00×

EBITDA Margin

63.60%

Financial Statements

As of FY2026 Annual · updated 20 Sept 2026
Disclosed reportedDerived calculated
Line itemFY2022FY2023FY2024FY2025FY2026
Total Income
Revenue from operationsDisclosed2.6₹ Crore1.95₹ Crore3.74₹ Crore3.12₹ Crore3.26₹ Crore
Other incomeDisclosed44.1₹ Lakh50.26₹ Lakh61.86₹ Lakh65.95₹ Lakh74.73₹ Lakh
Total IncomeDerived3.04₹ Crore2.45₹ Crore4.36₹ Crore3.78₹ Crore4₹ Crore
Expenses
Cost of goods soldDisclosed0₹ Crore0₹ Crore0₹ Crore0₹ Crore0₹ Crore
Purchases of stock-in-tradeDisclosed0₹ Crore0₹ Crore0₹ Crore0₹ Crore0₹ Crore
Changes in inventoriesDisclosed0₹ Crore0₹ Crore0₹ Crore0₹ Crore0₹ Crore
Employee benefits expenseDisclosed34.16₹ Lakh35.79₹ Lakh39.37₹ Lakh42.9₹ Lakh47.26₹ Lakh
Finance costsDisclosed0₹ Crore0₹ Crore0₹ Crore0₹ Crore29₹ Thousand
Depreciation and amortization expenseDisclosed16.82₹ Lakh18.88₹ Lakh22.51₹ Lakh23.17₹ Lakh25.99₹ Lakh
Manufacturing expensesDisclosed0₹ Crore0₹ Crore0₹ Crore0₹ Crore0₹ Crore
Operating expensesDisclosed0₹ Crore0₹ Crore0₹ Crore0₹ Crore0₹ Crore
Other expensesDisclosed15.41₹ Lakh17.05₹ Lakh92.53₹ Lakh1.6₹ Crore1.46₹ Crore
Total ExpensesDerived66.39₹ Lakh71.72₹ Lakh1.54₹ Crore2.26₹ Crore2.2₹ Crore
Profit
Exceptional itemsDisclosed0₹ Crore0₹ Crore0₹ Crore0₹ Crore0₹ Crore
Profit before taxDerived2.37₹ Crore1.73₹ Crore2.82₹ Crore1.52₹ Crore1.81₹ Crore
Current tax expenseDisclosed39.66₹ Lakh46.45₹ Lakh40.95₹ Lakh45.61₹ Lakh54.52₹ Lakh
Deferred tax expenseDisclosed-1.91₹ Lakh-4.21₹ Lakh43.18₹ Lakh-12.49₹ Lakh-7.59₹ Lakh
Tax expenseDisclosed37.75₹ Lakh42.24₹ Lakh84.13₹ Lakh33.12₹ Lakh46.93₹ Lakh
Profit After TaxDerived2₹ Crore1.31₹ Crore1.97₹ Crore1.19₹ Crore1.34₹ Crore
Other comprehensive incomeDisclosed97.91₹ Lakh-31.83₹ Lakh3.29₹ Crore2.13₹ Crore21.65₹ Lakh
Total Comprehensive IncomeDerived2.98₹ Crore99.17₹ Lakh5.27₹ Crore3.32₹ Crore1.56₹ Crore

Documents Library

Access all financial reports and filings

Annual Report

Annual Report 2025

2025
1.4 MB

Annual Report 2026

2026
1.3 MB

annual report 2022

2022
1.4 MB

annual report 2023

2023
1.7 MB

annual report 2024

2024
2.0 MB

Quarterly Report

6MFY2026 Results of sigachi Laboratories others Th

4.1 MB

9MFY26 Results of Sigachi Lab. others The consolid

0.8 MB

Q4FY2025 Results of Sigachi Laboratories others Th

2.3 MB

Sigachi Laboratories Q1fy26 Results others The con

3.0 MB

Income Statement

financial result 2024

2024
1.6 MB

financial result 2025

2025
2.3 MB

Shareholding Pattern

Resident Individual

40.75%

Promoters

36.98%

NRI

20.22%

Others

2.05%

S

Sri. T. Adinarayana

Chairman

30+

LinkedIn
S

Sri. T.R. Sekhar

Executive Director

25+

LinkedIn
M

Mr. B. Kumar

CFO

25+

LinkedIn

9MFY26 Results of Sigachi Lab. others The consolidated financial results for the quarter ending Dec 31, 2025 (Q3)

others
04/02/2026

9MFY26 Results of Sigachi Lab. others The consolidated financial results for the quarter ending Dec 31, 2025 (Q3)

6MFY2026 Results of sigachi Laboratories others The consolidated financial results for the quarter ending Sep 30, 2025 (Q2)

others
13/11/2025

6MFY2026 Results of sigachi Laboratories others The consolidated financial results for the quarter ending Sep 30, 2025 (Q2)

Sigachi Laboratories Q1fy26 Results others The consolidated financial results for the quarter ending June 30, 2025 (Q1)

others
16/08/2025

Sigachi Laboratories Q1fy26 Results others The consolidated financial results for the quarter ending June 30, 2025 (Q1)

Q4FY2025 Results of Sigachi Laboratories others The consolidated financial results for the quarter and year ending Mar 31, 2025 (Q4)

others
27/05/2025

Q4FY2025 Results of Sigachi Laboratories others The consolidated financial results for the quarter and year ending Mar 31, 2025 (Q4)

Express buy interest

No commitment — the desk will reach out

Current Price

₹52
+0.00%
Min lot: 1500
Price/share₹52
Quantity100
Estimated Total₹5,200

Secure & Verified Transaction

Unlisted shares are illiquid and carry higher market risks. Please read the Risk Disclosure before investing.

Talk to a Specialist

Get expert guidance on this investment

52 Week Range
₹52
₹52

About Sigachi Laboratories Limited Unlisted Shares unlisted shares

Indicative · updated daily

Sigachi Laboratories Limited unlisted share price today

Sigachi Laboratories Limited unlisted share price today is ₹52 as of 12 November 2026.

Sigachi Laboratories Limited Unlisted Shares — frequently asked questions

What is the grey market price for Sigachi Laboratories Limited?

No IPO is currently announced for Sigachi Laboratories Limited, so no grey market exists; the price above reflects Priveq's own desk valuation.

Has Sigachi Laboratories Limited filed for an IPO, and when might it list?

Sigachi Laboratories Limited has not filed a draft red herring prospectus, so no IPO is currently announced and no listing date has been set.

How does Sigachi Laboratories Limited compare to its listed peers?

There is no closely comparable listed company for Sigachi Laboratories Limited in India today.

Is Sigachi Laboratories Limited on the SME or Mainboard IPO track?

Sigachi Laboratories Limited has not filed a draft red herring prospectus, so no IPO track is set yet.

What is Sigachi Laboratories Limited's CIN and registered office?

Sigachi Laboratories Limited's Corporate Identity Number is L24230TG1994PLC018786, registered at Hyderabad, Telangana, India.

What is Sigachi Laboratories Limited's market capitalisation?

Sigachi Laboratories Limited's market capitalisation is approximately ₹35 crore, based on its current unlisted share price.

All Pharmaceuticals →

Buying, selling and holding unlisted shares

Applies to every company on Priveq
How do I buy Sigachi Laboratories Limited unlisted shares?

Priveq Investech Private Limited is the named counterparty on every transaction. To buy Sigachi Laboratories Limited unlisted shares: complete KYC once (PAN, Aadhaar, bank details, and demat account information — SEBI-compliant, typically approved within 24 hours), then submit your order through your Priveq dashboard specifying quantity. Our team confirms price and payment details with you directly. Once payment is confirmed, Sigachi Laboratories Limited shares are transferred off-market straight to your demat account, with no pooling and no middlemen.

How do I sell Sigachi Laboratories Limited unlisted shares?

Submit an Express Sell Interest for Sigachi Laboratories Limited through your Priveq dashboard, specifying quantity, the same way a buy order is placed. Priveq quotes you a bid price, which may differ from the live Buy price shown to buyers, since unlisted-share pricing works on a bid-ask basis rather than a single quote. Once you accept, you'll need to provide your Client Master List (CML), a cancelled cheque or bank details, and PAN. If you hold shares with CDSL, transfer can also be completed digitally via CDSL Easiest. You transfer Sigachi Laboratories Limited shares to Priveq first, and payment follows once the transfer is confirmed received, typically the same day, T+1, or occasionally T+2, communicated to you directly. For sizeable transactions worth crores of rupees, an escrow arrangement can be used instead, at the sole consent of both parties.

What is the minimum investment for Sigachi Laboratories Limited unlisted shares?

Minimum investment varies by company and is shown as the Min Investment figure on this page. Sigachi Laboratories Limited's minimum is ₹78,000.

Is there a maximum investment limit?

There's no fixed maximum investment limit for Sigachi Laboratories Limited unlisted shares. For sizeable transactions worth crores of rupees, an escrow arrangement can be used at the sole consent of both parties, the same mechanism available on the sell side.

Is buying Sigachi Laboratories Limited unlisted shares legal in India?

Yes. Buying and selling unlisted shares in India is legal and is subject to relevant SEBI regulations, including the mandatory lock-in period after listing, stamp duty, and depository participant charges on each transaction. Priveq's own KYC process is built to be SEBI-compliant.

What is the lock-in period for Sigachi Laboratories Limited unlisted shares?

Sigachi Laboratories Limited has not filed a DRHP yet, so no listing date or lock-in period applies at this stage. Once an IPO is filed, this answer updates to reflect the applicable SME or Mainboard lock-in.

What happens if Sigachi Laboratories Limited's IPO is delayed or withdrawn?

If an IPO is delayed, shares remain unlisted and continue to trade on the desk at Priveq's indicative price, with no lock-in in effect until an actual listing happens. If a company formally withdraws its DRHP, the same applies: shares stay unlisted, with no lock-in period until and unless a fresh IPO process begins.

How are capital gains on Sigachi Laboratories Limited unlisted shares taxed?

If you sell unlisted shares, including Sigachi Laboratories Limited, within 24 months of purchase, the gain is taxed as short-term capital gain at your applicable income tax slab rate. Beyond 24 months, it is taxed as long-term capital gain at 12.5 percent, without indexation benefit, under the rules effective from 23 July 2024. If Sigachi Laboratories Limited lists and you sell after listing, the applicable tax treatment shifts to listed-security rates, with the holding period still measured from your original unlisted purchase date. This is general information, not tax advice; investors should confirm their specific position with a tax advisor.

Can NRIs invest in Sigachi Laboratories Limited unlisted shares?

Yes, on a non-repatriable basis. NRIs can invest using funds from an NRO account; sale proceeds stay within India unless repatriated separately under RBI's own limits. Priveq does not currently support repatriable investment (NRE/FCNR-funded), which would require the investee company to file additional RBI paperwork as foreign direct investment.

Does Priveq charge a platform fee on top of the share price?

No. The price quoted to you is all-in; there is no separate platform fee or brokerage added on top.

How does Priveq determine the desk price for Sigachi Laboratories Limited?

Priveq's desk price reflects several inputs together, not a single formula: the seller's ask price at the time, current demand and supply on the platform for Sigachi Laboratories Limited specifically, broader sentiment in the unlisted and pre-IPO market, how Sigachi Laboratories Limited's sector and listed peers are trading, the company's own recent financial performance and IPO-stage developments, and recent transaction history where deals have actually closed.

Because unlisted shares trade over the counter rather than on an exchange, this price is indicative, not a continuously live quoted market price, and the actual deal price is confirmed with you directly before a transaction closes.

Is Priveq SEBI-registered? Does it give investment advice?

Priveq is not a SEBI-registered stock exchange and not a SEBI-registered investment adviser. Priveq Investech Private Limited operates Priveq.in as a research and information platform for unlisted and pre-IPO shares, and is the named counterparty on transactions executed through the platform. Nothing on this page is investment advice; it's information to help you evaluate a company and decide for yourself.

Am I eligible to invest through Priveq if I'm not an HNI?

Yes. Priveq isn't a stock exchange with membership restrictions, and investing isn't limited to HNIs. Depending on the company, entry points can start as low as ₹20,000, though the minimum for any specific company is shown as the Min Investment figure on its page.

What documents do I receive after buying unlisted shares?

You receive an email acknowledging and confirming your order, along with a deal note or invoice recording the transaction details.

What happens to my shares or money if a deal falls through?

Because Priveq is the direct counterparty on every transaction rather than just connecting a buyer and seller, this risk sits with Priveq, not with you. If a deal falls through after you've committed funds or shares, they remain safe, and Priveq guarantees a refund.

Chat with us